Trials / Completed
CompletedNCT00338650
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,000 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | adalimumab |
Timeline
- Start date
- 2006-06-01
- Completion
- 2007-05-01
- First posted
- 2006-06-20
- Last updated
- 2007-11-29
Locations
97 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00338650. Inclusion in this directory is not an endorsement.